加拿大Sophiris Bio www.sophirisbio.com 
Protox Therapeutics Inc. (溫哥華，Vancouver)宣布公司就PRX302藥物項(xiàng)目己向美國(guó)FDA提出攝護(hù)腺癌治療藥物的研究中新藥申請(qǐng)(investigational new drug， IND)。一旦在FDA的IND案通過(guò)，公司預(yù)期便可以在下一年進(jìn)行復(fù)發(fā)型部位固定攝護(hù)腺癌臨床第一期測(cè)試。

2012年加拿大Protox Therapeutics Inc 改名為Sophiris Bio

Protox Therapeutics uses genetic engineering to transform naturally occurring proteins into novel targeted therapeutics for the treatment of prostate diseases and various cancers. Protox is advancing a pipeline of clinical-stage product candidates derived from its PORxin™ and INxin™ technology platforms. Protox’s lead drugs currently in clinical development include PRX302 for the treatment of benign prostatic hyperplasia (BPH, commonly known as enlarged prostate) and localized prostate cancer, as well as PRX321 for primary brain cancer (glioblastoma multiforme and astrocytoma).